Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Date:10/23/2007

NEW YORK, Oct. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Thursday, October 25, 2007 at 8:30 a.m. EDT to discuss the Third Quarter 2007 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-800-909-7113 (U.S.), 1-785-830-1914 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral anti-cancer agent that inhibits activation of Akt, a protein in the body associated with tumor survival and growth, and modulates a number of other key signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Digital Healthcare Conference 2007: Mounting obstacles for health IT
2. Biomedical engineering conference invites manufacturers
3. Conference to address small town development
4. Wisconsin to host SBIR Conference
5. Gaming conference explores interactive media in learning
6. Digital Healthcare Conference starts on a realistic note
7. Digital Healthcare Conference marks Wisconsins Healthcare IT Week
8. Third coast of biotechnology makes strong showing at VC conference
9. Why companies dont get invited to the DEMO conference
10. Giuliani will keynote RedPrairie Corporations user conference
11. Wicab to present BrainPort at Boston conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Genome Diagnostics Inc. (PGDx) today announced that it has three ... (AACR) Annual Meeting 2017, being held April 1-5, 2017, in ... that five scientists associated with PGDx—two co-founders and three scientific ... Science Award. ... Doug Ward , CEO of Personal Genome Diagnostics, ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... organization dedicated to finding cures for inflammatory bowel diseases (IBD), and ReachMD ... to deliver exclusive content to ReachMD learners. , The partnership, which launched ...
(Date:3/29/2017)... Inc. (NASDAQ: VRML), a bio-analytical solutions company focused ... the fourth quarter and full year ended December ... year for us with our first clinical utility ... reimbursement progress with Medicare, positive medical policy coverage ... cleared our 2 nd generation product Overa ...
(Date:3/29/2017)... , March 29, 2017 "Surging application of ... by the government are expected to drive the growth ... The gesture recognition market is expected to be worth ... of 29.63% between 2017 and 2022. The touchless sensing ... by 2022, growing at a CAGR of 17.44% between ...
Breaking Biology Technology:
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
Breaking Biology News(10 mins):